Bengaluru, Oct. 26 -- India's Contract Research, Development, and Manufacturing Organization (CRDMO) sector is poised for a transformative leap, with projections indicating an expansion from its current valuation of $3-3.5 billion to a robust $22-25 billion by 2035.

This growth trajectory is detailed in the Unleashing the Tiger: Indian CRDMO Sector 2025, published by Boston Consulting Group (BCG) in collaboration with the Innovative Pharmaceutical Services Organisation (IPSO).

The Indian CRDMO industry has demonstrated a compound annual growth rate (CAGR) of 15% from 2019 to 2024, surpassing the global average of 7-8%. This momentum is further fueled by global supply chain realignments, with Western pharmaceutical companies seeking alte...